If any controlled substance appears in the listed bulk database, please ignore it, as we do not supply or offer controlled substances.
Celecoxib Bromo Impurity
100% accuracy
of data
24/7 scientific
support
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

170570-75-9Celecoxib Bromo Impurity

● In Stock

Catalogue No.:VE007713
CAS No.:170570-75-9
Mol. Formula:C17H13BrF3N3O2S
Mol. Weight:460.27 g/mol

Additional information on CAS 170570-75-9

Parent drug

Celecoxib

IUPAC Name

4-(5-(4-(Bromomethyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

Synonyms

N/A

Description

It is a selective cyclooxygenase-2 inhibitor, By inhibiting prostaglandin synthesis non-steroidal anti-inflammatory drugs cause mucosal damage and ulceration. Celecoxib poses less of an ulceration risk than other NSAIDS, owing to its decreased effect on gastric mucosal prostaglandin synthesis when compared to placebo, also exerts anticancer effects by binding to the cadherin-11 protein, which is involved in the progression of tumors and inhibiting the 3 phosphoinositide-dependent kinase-1 signaling mechanism, which is used to treat osteoarthritis, rheumatoid arthritis, and to reduce polyps in familial adenomatous polyposis.

References

Xu, C., Gu, K., Yasen, Y., & Hou, Y. (2016). Efficacy and Safety of Celecoxib Therapy in Osteoarthritis. Medicine, 95(20), e3585. https://doi.org/10.1097/md.0000000000003585

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
Products quotation
Name
Url
 
This field is hidden when viewing the form
This field is hidden when viewing the form